In acute ischemic stroke, early IV tenecteplase was noninferior to alteplase for excellent functional outcome

Emma Ferguson; Eddy Lang

doi:10.7326/J22-0090

In acute ischemic stroke, early IV tenecteplase was noninferior to alteplase for excellent functional outcome

Ann Intern Med. 2022 Nov;175(11):JC124. doi: 10.7326/J22-0090. Epub 2022 Nov 1.

Authors

Emma Ferguson¹, Eddy Lang²

Affiliations

¹ University of Ottawa, Ottawa, Ontario, Canada (E.F.).
² University of Calgary, Calgary, Alberta, Canada (E.L.).

PMID: 36315948
DOI: 10.7326/J22-0090

Abstract

Menon BK, Buck BH, Singh N, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet. 2022;400:161-9. 35779553.

Publication types

Equivalence Trial
Multicenter Study
Pragmatic Clinical Trial
Comment

MeSH terms

Brain Ischemia* / drug therapy
Fibrinolytic Agents / therapeutic use
Humans
Ischemic Stroke* / drug therapy
Tenecteplase* / therapeutic use
Tissue Plasminogen Activator* / therapeutic use
Treatment Outcome

Substances

Fibrinolytic Agents
Tenecteplase
Tissue Plasminogen Activator